COPENHAGEN, Denmark I May 20, 2016 I Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the first participants have been dosed in a clinical study of a DuoBody® bispecific antibody under Genmab’s DuoBody technology platform collaboration with Janssen Biotech, Inc. (Janssen). The Phase I study investigates the human bispecific antibody JNJ-61178104, which is directed to two inflammatory disease targets, for potential use in treating autoimmune disorders.
Genmab will receive a $2 million milestone payment for the progress in the study.
The DuoBody collaboration with Janssen has been a productive one marked by rapid progress with a total of 12 programs activated. Seven clinical candidates have been selected for development by Janssen and three DuoBody programs are entering the clinic.
“Genmab’s DuoBody platform creates bispecific antibodies that can be directed to two targets at once and we believe the technology has the potential to offer fundamentally new treatment options for certain diseases including inflammatory diseases and cancer. Today’s news marks the first time a DuoBody product has been administered in a clinical study and is a significant step forward for the DuoBody platform and a credit to our scientists who invented this innovative and highly versatile next generation antibody technology,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
About the DuoBody Technology Collaboration with Janssen
Under the original July 2012 agreement, Janssen has the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. Genmab received an upfront payment of $3.5 million from Janssen and will potentially be entitled to milestone and license payments of up to approximately $175 million, as well as royalties for each commercialized DuoBody product.
Under the terms of a December 2013 amendment, Janssen is entitled to work on up to ten additional programs. Genmab received an initial payment of $2 million from Janssen. For each of the ten additional programs that Janssen successfully initiates, develops and commercializes, Genmab will potentially be entitled to receive average milestone and license payments of approximately $191 million. In addition, Genmab will be entitled to royalties on sales of any commercialized products.
About the DuoBody Platform
The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies’ specificity and efficacy. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab’s DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab’s technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
SOURCE: Genmab
Post Views: 177
COPENHAGEN, Denmark I May 20, 2016 I Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the first participants have been dosed in a clinical study of a DuoBody® bispecific antibody under Genmab’s DuoBody technology platform collaboration with Janssen Biotech, Inc. (Janssen). The Phase I study investigates the human bispecific antibody JNJ-61178104, which is directed to two inflammatory disease targets, for potential use in treating autoimmune disorders.
Genmab will receive a $2 million milestone payment for the progress in the study.
The DuoBody collaboration with Janssen has been a productive one marked by rapid progress with a total of 12 programs activated. Seven clinical candidates have been selected for development by Janssen and three DuoBody programs are entering the clinic.
“Genmab’s DuoBody platform creates bispecific antibodies that can be directed to two targets at once and we believe the technology has the potential to offer fundamentally new treatment options for certain diseases including inflammatory diseases and cancer. Today’s news marks the first time a DuoBody product has been administered in a clinical study and is a significant step forward for the DuoBody platform and a credit to our scientists who invented this innovative and highly versatile next generation antibody technology,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
About the DuoBody Technology Collaboration with Janssen
Under the original July 2012 agreement, Janssen has the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. Genmab received an upfront payment of $3.5 million from Janssen and will potentially be entitled to milestone and license payments of up to approximately $175 million, as well as royalties for each commercialized DuoBody product.
Under the terms of a December 2013 amendment, Janssen is entitled to work on up to ten additional programs. Genmab received an initial payment of $2 million from Janssen. For each of the ten additional programs that Janssen successfully initiates, develops and commercializes, Genmab will potentially be entitled to receive average milestone and license payments of approximately $191 million. In addition, Genmab will be entitled to royalties on sales of any commercialized products.
About the DuoBody Platform
The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies’ specificity and efficacy. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab’s DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab’s technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
SOURCE: Genmab
Post Views: 177
